Autologous T cells genetically engineered to express chimeric antigen receptors that recognize tumor antigens and activate T cells via CD3 signaling to kill malignant cells.
Autologous T cells are engineered to express a chimeric antigen receptor that binds tumor-associated antigens independent of MHC and activates T-cell signaling (CD3ζ with costimulatory domains such as CD28 or 4-1BB), leading to proliferation and targeted cytotoxic killing of malignant cells via perforin/granzyme release and cytokine-mediated immune activation.
CD19-targeted CAR T cells bind CD19 on target cells, triggering CAR (CD3ζ + costimulatory) signaling and killing via perforin/granzyme-mediated cytolysis and Fas–FasL apoptosis.
Autologous T cells genetically engineered to express chimeric antigen receptors that recognize tumor antigens and activate T cells via CD3 signaling to kill malignant cells.
Autologous T cells are engineered to express a chimeric antigen receptor that binds tumor-associated antigens independent of MHC and activates T-cell signaling (CD3ζ with costimulatory domains such as CD28 or 4-1BB), leading to proliferation and targeted cytotoxic killing of malignant cells via perforin/granzyme release and cytokine-mediated immune activation.
BCMA-specific CAR T cells bind BCMA on target cells and, upon CAR (CD3ζ±costim) activation, kill them via perforin/granzyme-mediated lysis and apoptosis (with additional Fas/FasL and cytokine-mediated cytotoxicity).
Bispecific monoclonal antibodies that bind a tumor-associated antigen and CD3 on T cells to redirect cytotoxic T-cell activity against malignant cells.
Bispecific monoclonal antibodies that simultaneously bind CD3 on T cells and a tumor-associated antigen on malignant cells, crosslinking T cells to tumor targets to trigger CD3-mediated activation, immunologic synapse formation, and perforin/granzyme-mediated cytotoxic killing.
The bispecific antibody binds CD19 on target cells and CD3 on T cells, forming an immunologic synapse that activates T cells to kill CD19+ cells via perforin/granzyme-mediated cytotoxicity (and Fas–FasL apoptosis).
Bispecific monoclonal antibodies that bind a tumor-associated antigen and CD3 on T cells to redirect cytotoxic T-cell activity against malignant cells.
Bispecific monoclonal antibodies that simultaneously bind CD3 on T cells and a tumor-associated antigen on malignant cells, crosslinking T cells to tumor targets to trigger CD3-mediated activation, immunologic synapse formation, and perforin/granzyme-mediated cytotoxic killing.
The bispecific antibody binds BCMA on target cells and CD3 on T cells, forming an immunologic synapse that activates T cells to release perforin and granzymes, inducing apoptosis of BCMA-expressing cells.
Bispecific monoclonal antibodies that bind a tumor-associated antigen and CD3 on T cells to redirect cytotoxic T-cell activity against malignant cells.
Bispecific monoclonal antibodies that simultaneously bind CD3 on T cells and a tumor-associated antigen on malignant cells, crosslinking T cells to tumor targets to trigger CD3-mediated activation, immunologic synapse formation, and perforin/granzyme-mediated cytotoxic killing.
CD20×CD3 bispecific antibodies bridge T cells to CD20+ cells, activating T cells via CD3 to form an immunologic synapse and kill the target cell through perforin/granzyme-mediated cytolysis and apoptosis.